产品
编 号：F292928
分子式：C49H62N10O16S3
分子量：1143.27
分子式：C49H62N10O16S3
分子量：1143.27
产品类型
规格
价格
是否有货
1mg
880
In-stock
5mg
2400
In-stock
10mg
3840
In-stock
结构图
CAS No: 25126-32-3
产品详情
生物活性：
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK.
体内研究：
Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model.Animal Model:MI rat model
Dosage:50 μg/kg
Administration:i.p.; 50 μg/kg/d; for 4 weeks
Result:Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.
体外研究：
Sincalide (Cholecystokinin octapeptide, CCK‐8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. CCK‐8 also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway.
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK.
体内研究：
Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model.Animal Model:MI rat model
Dosage:50 μg/kg
Administration:i.p.; 50 μg/kg/d; for 4 weeks
Result:Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.
体外研究：
Sincalide (Cholecystokinin octapeptide, CCK‐8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. CCK‐8 also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备